ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Pediatric rheumatology"

  • Abstract Number: 0380 • ACR Convergence 2024

    Joint Acoustic Emissions as a Digital Biomarker for Knee Inflammation in Juvenile Idiopathic Arthritis: A Pilot Study Using Musculoskeletal Ultrasound as Ground Truth

    Quentin Goossens1, Christopher Nichols1, Diana Sofia Villacis-Nunez2, Lori Ponder3, Omer Inan4 and Sampath Prahalad5, 1Georgia Institute of Technology, Atlanta, GA, 2Emory University School of Medicine, Atlanta, GA, 3Children's Healthcare of Atlanta, Atlanta, GA, 4Georgia Institute of Technology, Marietta, GA, 5Emory + Children's Pediatric Institute, Atlanta, GA

    Background/Purpose: Juvenile idiopathic arthritis (JIA) is a chronic childhood arthropathy affecting 1 in 1000 children under 16, classified into seven categories by ILAR. Commonly, JIA…
  • Abstract Number: 0404 • ACR Convergence 2024

    Methotrexate Adherence in JIA: Use of Electronic Health Record-Linked Pharmacy DispensingData

    Dori Abel1, David Anderson1, Michael Kallan2, Levon Utidjian3, Jon Burnham4, Joyce Chang5, Chen Kenyon3 and Sabrina Gmuca1, 1Children's Hospital of Philadelphia, Philadelphia, PA, 2University of Pennsylvania, Philadelphia, 3Children's Hospital of Philadelphia, Philadelphia, 4Children's Hospital of Philadelphia, Bryn Mawr, PA, 5Boston Children's Hospital, Boston, MA

    Background/Purpose: The extent to which adherence to prescribed treatment regimens contributes to differential disease outcomes in JIA – and demographic disparities in these outcomes –…
  • Abstract Number: 1028 • ACR Convergence 2024

    Assessment of Patient-Reported Outcomes in Juvenile Idiopathic Arthritis by Race, Ethnicity, and Insurance Type in the Pediatric Rheumatology Care and Outcomes Improvement Network Registry

    Julia Harris1, Nancy Pan2, Catherine Bingham3, Sheetal Vora4, Cagri Yildirim-Toruner5, Kerry Ferraro6, Erik Friedrichsen7, Michelle Batthish8, Jon Burnham9, Danielle Fair10, Suhas Ganguli11, Mileka Gilbert12, Beth Gottlieb13, Olha Halyabar14, Melissa Hazen15, Tzielan Lee16, Daniel Lovell17, Melissa Mannion18, Edward Oberle19, Linda Ray20, Michael Shishov21, Mary Toth22 and Esi Morgan23, 1Children's Mercy Kansas City, Overland Park, KS, 2Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, 3Penn State Children’s Hospital, Hershey, 4Atrium Health Levine Children's Hospital, Charlotte, NC, 5Baylor College of Medicine/ Texas Children's Hospital, Houston, TX, 6JIA parent and CHOP volunteer, Lower Gwynedd, PA, 7Seattle Children's Hospital, Seattle, 8McMaster Children's Hospital, Hamilton, ON, Canada, 9Children's Hospital of Philadelphia, Philadelphia, PA, 10Medical College of Wisconsin/Children's Wisconsin, Wauwatosa, WI, 11Hackensack University Medical Center, Hackensack, 12Medical University of South Carolina, Charleston, SC, 13Cohen Children's Medical Center, Lake Success, NY, 14Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, 15Boston Children's Hospital, Boston, MA, 16Stanford University School of Medicine, Palo Alto, CA, 17Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 18University of Alabama at Birmingham, Birmingham, AL, 19Nationwide Children's Hospital, Columbus, OH, 20University of Mississippi Medical Center, Jackson, MS, 21Phoenix Children's Hospital, Phoenix, AZ, 22Nemours Foundation, Orlando, FL, 23Seattle Children's Hospital, Seattle, WA

    Background/Purpose: As healthcare moves towards more patient-centered care, it is increasingly important to integrate patients’ opinions into clinical assessments and decision-making. The Pediatric Rheumatology Care…
  • Abstract Number: 1269 • ACR Convergence 2024

    Altered Tryptophan Metabolism in Juvenile Dermatomyositis Is Associated with Muscle Damage and Mental Health

    Yang Wu1, Aviya Lanis2, Jorge Armando Gonzalez-Chapa3, Jia Shi1, qian wang4, Mengtao Li4, Xiaofeng Zeng5, Susan Shenoi6 and Christian Lood3, 1University of Washington, Seattle, 2Seattle Children's Hospital, Seattle, 3University of Washington, Seattle, WA, 4Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China 2National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology, Beijing, China, 5Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, 6Seattle Children's Hospital and Research Center, Mercer Island, WA, WA

    Background/Purpose: Children with juvenile dermatomyositis (JDM) and juvenile idiopathic arthritis (JIA) experience impaired quality of life and high rates of anxiety and depression. The underlying…
  • Abstract Number: 1305 • ACR Convergence 2024

    Bingo: A Winning Pediatric Rheumatology Teaching Strategy?

    Kyla Fergason1, Michael DiLeo2, Amanda Braddock3 and Miriah Gillispie-Taylor2, 1Baylor College of Medicine, Houston, TX, 2Baylor College of Medicine/Texas Children's Hospital, Houston, TX, 3UTSW, Dallas

    Background/Purpose: Exposure to pediatric rheumatology is often lacking during training given that 33% of medical schools and 36% of residency programs have no affiliated pediatric…
  • Abstract Number: 1777 • ACR Convergence 2024

    Broad Proteomic Analysis Reveals Top Differential Protein Modules and Functional Annotations with Clinical Traits in Juvenile Dermatomyositis (JDM) and Myositis-Specific Autoantibody (MSA) Groups

    Amy Kaneshiro1, Adeline Chin1, Lisa Rider2, Frederick Miller3, Foo Cheung4, Megan Darrell1, Angelique Biancotto4, Ujana Zajmi1 and Hanna Kim5, 1NIH/NIAMS, Bethesda, MD, 2NIEHS, NIH, Garrett Park, MD, 3NIH, NIEHS, Chapel Hill, NC, 4NIH/NIAID, Bethesda, MD, 5National Institute of Arthritis Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD

    Background/Purpose: JDM is a heterogenous systemic autoimmune disease with muscle and skin pathology, which can be clinically subgrouped by MSAs (ex: anti-TIF1, anti-MDA5 autoantibodies (Ab)).…
  • Abstract Number: 2043 • ACR Convergence 2024

    Evaluation of Medication Adherence of FMF Patients Transitioned from a Pediatric Clinic to an Adult Clinic: A Cross-sectional Study

    Fatma Zehra Avci1, Feyza Nur Azman2, Elif Sila Unsal3 and Serdal Ugurlu4, 1Department of Internal Medicine, Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa, Istanbul, Turkey, 2Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, 3Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa, Istanbul, Turkey, Istanbul, 4Istanbul University-Cerrahpasa, Istanbul, Turkey

    Background/Purpose: Familial Mediterranean Fever (FMF) typically begins in childhood. It has been demonstrated that colchicine can reduce FMF attacks, prevent the development of amyloidosis, and…
  • Abstract Number: 2193 • ACR Convergence 2024

    Prospective Evaluation of Reactogenicity and Safety Following COVID-19 Vaccination in Children with a History of MIS-C

    Mariana Sanchez Villa1, Jessica Nguyen2, Danielle Guffey3, Leila Sahni4, Miriah Gillispie-Taylor5, Marietta De Guzman2, S. Kristen Sexson Tejtel2, Sridevi Devaraj4, Flor Munoz4 and Tiphanie Vogel2, 1Baylor college of Medicine, Huffman, TX, 2Baylor College of Medicine, Houston, TX, 3Baylor College of Medicine, Houston, 4Baylor COM, Houston, TX, 5Baylor College of Medicine/Texas Children's Hospital, Houston, TX

    Background/Purpose: A rare subset of children who contract SARS-CoV-2 later develop the hyperinflammatory condition known as multisystem inflammatory syndrome in children (MIS-C). There has been…
  • Abstract Number: 2500 • ACR Convergence 2024

    Description of Patients with Refractory Kawasaki Disease at a Large Tertiary Center

    Jessica Nguyen1, Danielle Guffey2, Andrea Ramirez1, Jamie Lai3, Tiphanie Vogel1, S. Kristen Sexson Tejtel1, Cagri Yildirim-Toruner4 and Marietta DeGuzman1, 1Baylor College of Medicine, Houston, TX, 2Baylor College of Medicine, Houston, 3Baylor College of Medicine, The Woodlands, TX, 4Baylor College of Medicine/ Texas Children's Hospital, Houston, TX

    Background/Purpose: Kawasaki disease (KD) is the leading cause of acquired heart disease in developed countries due to the development of coronary artery aneurysms (CAAs). Intravenous…
  • Abstract Number: 2628 • ACR Convergence 2024

    Clinical Features, Treatments, and Outcomes of a Large International Cohort of Childhood-onset Takayasu Arteritis: A PedVas Study

    James Bistolarides1, Vidya Sivaraman2, Else Bosman3, Linda Wagner-Weiner4, Kimberly Morishita5, James Nocton1, Melodee Liegl1, Amy Pan1 and David Cabral6, and PedVas Investigators Network, 1Medical College of Wisconsin, Milwaukee, WI, 2Nationwide Children's Hospital/ The Ohio State University, Columbus, OH, 3UBC, Vancouver, BC, Canada, 4University of Chicago, Chicago, IL, 5University of British Columbia - Vancouver, Vancouver, BC, Canada, 6BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada

    Background/Purpose: Takayasu arteritis (TAK) is a rare systemic vasculitis. It occurs most commonly in patients aged < 40 years (y), and 32% of patients present…
  • Abstract Number: 0382 • ACR Convergence 2024

    Comparative Analysis of Tear-based S100 Proteins, Cytokines, and Chemokines Levels in Juvenile Idiopathic Arthritis Associated-uveitis: Insights into Eye Laterality and Severity of Ocular Inflammation

    Ilaria Maccora1, Mariia Pavlenko2, Jackeline Rodriguez-Smith3, Amy Cassedy4, Mekibib Altaye5, hermine brunner6, Alexandra Duell5, Alexei Grom5, Theresa Hennard7, Virginia Miraldi Utz5, Najima Mwase5, Megan Quinlan-Waters5, grant schulert5, Alyssa Sproles8, Jessica Shantha9, Sunil K Srivastava10, Sherry Thornton8, Steven Yeh11 and sheila Angeles-Han12, 1?PhD student, in the Area of Drugs and Innovative Treatments, NeuroFARBA Department, University of Florence. Meyer Children's Hospital, Florence Italy, Firenze, Florence, Italy, 2Division of Rheumatology, Cincinnati Children`s Hospital Medical Center, Cincinnati, OH, 3Division of Rheumatology, Cincinnati Children’s Hospital Medical Center and Department of Pediatrics, University of Cincinnati, Cincinnati, OH, Cincinnati, OH, 4Division of Biostatistics and Epidemology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, Cincinnati, OH, 5Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 6Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, 7Cincinnati Children's Hospital and Medical Center, Cincinnati, OH, 8Cincinnati Children's Hospital, Cincinnati, 9UCSF/Proctor Foundation, San Francisco, IL, 10Cole Eye Institute, Cleveland Clinic;, Cleveland, OH, 11Truhlsen Eye Institute, University of Nebraska Medical Center., Nebraska, NE, 12Cincinnati Children's Hospital, Cincinnati, OH

    Background/Purpose: Juvenile idiopathic arthritis-associated uveitis (JIA-U) is an ocular disease that can be unilateral or bilateral. Measurement of ocular inflammation is performed by ophthalmic examination…
  • Abstract Number: 0405 • ACR Convergence 2024

    Olokizumab, a Monoclonal Antibody Against IL-6, in Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA): Results of 24 Weeks of the Phase 2 Open-label Clinical Trial

    Ekaterina Alexeeva1, Tatiana Dvoryakovskaya2, Elena Zholobova3, Elizaveta Krekhova4, Rinat Raupov5, Daria Bukhanova6, Alina Egorova6, Sofia Kuzkina6, Mikhail Samsonov6, Irina Nikishina7 and Mikhail Kostik5, 1National Medical Research Center of Children's Health, Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation, Moscow, Russia, 2National Medical Research Center of Children's Health, Moscow, Russia, 3Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation, Moscow, Russia, 4National Medical Research Centre for Children's Health, Moscow, Russia, 5Saint-Petersburg State Pediatric Medical University, Saint Petersburg, Russia, 6R-Pharm, Moscow, Russia, 7V. A. Nasonova Research Institute of Rheumatology, Moscow, Russia

    Background/Purpose: Olokizumab (OKZ) is a direct interleukin-6 inhibitor for treatment of rheumatoid arthritis and is being investigated in the open-label Phase 2 trial in adolescents…
  • Abstract Number: 1058 • ACR Convergence 2024

    Bridging the Care Gap Between Hospital Discharge and Outpatient Care Transition for Pediatric Rheumatology Patients: An RN-led Quality Improvement Project

    Adrienne Ramirez1, Lisa Walker-Vischer2 and Tzielan Lee3, 1Stanford Medicine - Children's Health, Palo Alto, CA, 2San Jose State University, Campbell, CA, 3Stanford University School of Medicine, Palo Alto, CA

    Background/Purpose: When pediatric rheumatology patients are discharged from a hospital, the period between hospital discharge & outpatient care transition creates a care gap when there…
  • Abstract Number: 1270 • ACR Convergence 2024

    Association of Disease-Modifying Anti-Rheumatic Drug Selection with Hospitalized Infection in Youth with Childhood-Onset Systemic Lupus Erythematosus

    Jordan Roberts1, Anna Faino2, Marshall Brown3, Gabrielle Alonzi4, Mersine Bryan5, Cordelia Burn6, Joyce Chang4, Jonathan Cogen7, Nidhi Naik8, Kareena Patel9, Emily Zhang4, Mary Beth Son10 and Esi Morgan1, 1Seattle Children's Hospital, Seattle, WA, 2Seattle Children's Research Institute, Core for Biostatistics, Epidemiology and Analytics in Research, Seattle, 3Core for Biostatistics, Epidemiology and Analytics in Research, Seattle Children's Research Institute, Seattle, WA, 4Boston Children's Hospital, Boston, MA, 5Division of Hospital Medicine, Seattle Children's Hospital, Seattle, WA, 6Seattle Children's Hospital, Boston Children's Hospital, Seattle, 7Seattle Children’s Hospital, Seattle, WA, 8Seattle children's hospital, Bothell, WA, 9Seattle Children's Hospital, Seattle, 10Boston Children's Hospital, Brookline, MA

    Background/Purpose: Youth with childhood-onset systemic lupus erythematosus (cSLE) have increased risk of serious infection. It is unknown how much of this risk is due to…
  • Abstract Number: 1317 • ACR Convergence 2024

    Serum (1-3)-β-D-Glucan Levels in Juvenile Idiopathic Arthritis

    Yasmine LAMROUS, Camille LEGLISE, Audrey VANRENTERGHEM, Taieb CHOUAKI and Djamal-Dine DJEDDI, CHU AMIENS PICARDIE, AMIENS, France

    Background/Purpose: Juvenile idiopathic arthritis (JIA) encompasses the most common chronic rheumatologic manifestations in children. It results from the interplay of genetic, environmental, and infectious factors.…
  • « Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • 52
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology